Afatinib Recruiting Phase 2 Trials for Triple Negative Breast Cancer (TNBC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02511847Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib